IDKmonitor® Vedolizumab Drug Level ELISA (Health Canada)

The IDKmonitor® Vedolizumab Drug Level ELISA (Health Canada) is intended for the quantitative determination of free vedolizumab (therapeutic antibody against α4β7 integrin, e.g., ENTYVIO®) in EDTA plasma and serum.

Health Canada Licensed. For Laboratory Professional Use Only.

Not for sale in the U.S. Please contact us to order or get a quote.

If you are in the U.S., you can purchase the RUO version of the test.

IDKmonitor® Resources

Download our IDKmonitor® ELISAs brochure to discover more.

Test Principle of the IDKmonitor® Vedolizumab Drug Level ELISA (Health Canada)

In the first incubation step, the free vedolizumab from the sample is bound to the specific monoclonal anti-vedolizumab antibody coated on the plate. To remove all unbound substances, a washing step is carried out. In a further incubation step, a Peroxidase-labeled antibody is added. Tetramethylbenzidine (TMB) is used as a substrate for peroxidase. Finally, an acidic stop solution is added to terminate the reaction.

The color changes from blue to yellow. The intensity of the yellow color is directly proportional to the concentration of free vedolizumab in the sample.

A dose-response curve of the absorbance unit (optical density, OD at 450 nm) vs. concentration is generated using the values obtained from the standard. The presence of free vedolizumab in the samples is determined directly from this curve.